How do I convert a patient from intravenous levothyroxine (Synthroid) to an oral levothyroxine dose?

Converting IV Levothyroxine to Oral Administration

When transitioning from intravenous to oral levothyroxine, administer 70% or less of the IV dose as the initial oral dose, then titrate based on TSH response measured 4–8 weeks later. 1

Conversion Ratio and Rationale

• Approximately 70% of orally administered levothyroxine is absorbed under optimal conditions, compared to 100% bioavailability with IV administration. 1

• The American Association of Clinical Endocrinologists and American Thyroid Association recommend that patients unable to take oral levothyroxine should initially receive 70% or less of their usual oral dose intravenously—the inverse conversion applies when switching from IV to oral. 1

• Start with the oral dose equal to approximately 140% of the IV dose (dividing the IV dose by 0.7), recognizing that individual absorption may vary and require subsequent adjustment. 1

Step-by-Step Conversion Algorithm

1. Calculate the initial oral dose: Multiply the current IV dose by approximately 1.4 (or divide by 0.7) to account for the ~70% oral bioavailability. 1

2. Administer the oral dose on an empty stomach, 30–60 minutes before breakfast with water, or at bedtime ≥4 hours after the last meal to maximize absorption. 1, 2

3. Separate levothyroxine from interfering substances by at least 4 hours, including calcium, iron supplements, antacids, proton-pump inhibitors, and bile-acid sequestrants. 2, 3

4. Measure serum TSH 4–8 weeks after the conversion to assess adequacy of the new oral regimen and guide further dose adjustments. 1, 2

5. Adjust the oral dose in increments of 12.5–25 µg based on TSH results and clinical response until the target TSH range (0.3–4.1 mIU/L for primary hypothyroidism) is achieved. 2, 4

Special Considerations by Clinical Context

Patients with Malabsorption or Enteral Feeding

• For patients receiving enteral nutrition through nasogastric or other feeding tubes, administer crushed levothyroxine suspended in water; interrupt feeding for as long as possible before the dose and resume feeding at least 1 hour afterward. 1

• If feeding cannot be interrupted, consider continuing IV levothyroxine solution (when available) until normal oral intake and gastrointestinal function are restored. 1

• True levothyroxine malabsorption is rare; most cases of persistently elevated TSH despite high oral doses (>200 µg/day) reflect non-compliance rather than absorption defects. 4, 5

Critically Ill or Post-Surgical Patients

• Intravenous levothyroxine is indicated when patients have insufficient gastrointestinal absorption, partial or total loss of consciousness, sedation in the ICU, or shock. 6

• Once the patient can reliably swallow and gastrointestinal function is adequate, transition to oral therapy using the 70% bioavailability conversion. 6

Myxedema Coma

• Administer IV levothyroxine for 3–10 days until the patient can take oral medication and normal gastrointestinal absorption is restored by achieving at least peripheral euthyroidism. 6

• Transition to oral levothyroxine once the patient is alert, able to swallow safely, and gastrointestinal motility has normalized. 6

Monitoring and Dose Titration After Conversion

• Re-check TSH 4–8 weeks after initiating oral therapy or after any dose change to allow steady-state levels to be reached. 2, 4

• Smaller dose adjustments (12.5 µg) may require the full 8-week interval before TSH plateaus, particularly in elderly patients or those with coronary disease. 2, 4

• Once TSH is stable within the target range, monitor every 6 months initially, then annually. 2, 4

Common Pitfalls and How to Avoid Them

• Do not assume 1:1 dose equivalence between IV and oral routes; failure to account for the ~30% reduction in oral bioavailability will result in undertreatment. 1

• Verify medication adherence before escalating the oral dose if TSH remains elevated; non-compliance is the most frequent cause of apparent treatment failure. 4, 5

• Ensure proper oral administration technique: taking levothyroxine with food, coffee, or within 4 hours of interfering medications drastically reduces absorption and mimics malabsorption. 1, 2, 3

• In patients with coronary heart disease, use smaller dose increments (12.5 µg) and monitor for anginal symptoms with each adjustment to avoid precipitating cardiac ischemia. 2, 7

• For elderly patients (≥65 years), reduce the calculated oral dose by an additional 20–25% because of lower lean body mass and slower thyroxine degradation, then titrate cautiously to avoid overtreatment and atrial fibrillation. 2, 7

Alternative Formulations When Standard Tablets Fail

• Liquid oral levothyroxine or softgel capsules may improve absorption in patients with documented malabsorption or those taking proton-pump inhibitors, though these formulations are not universally available. 5, 8

• Intramuscular or subcutaneous levothyroxine can be considered if oral and IV routes are both unavailable, though case reports suggest weekly IV dosing followed by oral conversion is superior and safer. 9, 5